Embecta Corp (EMBC)vsNovartis AG ADR (NVS)
EMBC
Embecta Corp
$3.90
-57.84%
HEALTHCARE · Cap: $547.78M
NVS
Novartis AG ADR
$148.34
+1.95%
HEALTHCARE · Cap: $275.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 5140% more annual revenue ($56.58B vs $1.08B). NVS leads profitability with a 23.9% profit margin vs 12.9%. EMBC trades at a lower P/E of 3.9x. EMBC earns a higher WallStSmart Score of 56/100 (C).
EMBC
Buy56
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.6%
Fair Value
$46.96
Current Price
$3.90
$43.06 discount
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$148.34
$38.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 29.2%
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 0.3%
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
EMBC carries more volatility with a beta of 1.05 — expect wider price swings.
EMBC is growing revenue faster at -0.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
EMBC scores higher overall (56/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a premier medical technology company specializing in innovative insulin delivery solutions for diabetes management. As a strategic spin-off from Becton, Dickinson and Company, Embecta utilizes state-of-the-art technologies and a diverse product portfolio, including insulin pens and syringes, to optimize patient care and improve health outcomes. With a strong commitment to operational excellence and a customer-centric approach, Embecta is well-positioned to seize growth opportunities in the rapidly evolving diabetes care market, aiming to enhance patient experiences while solidifying its leadership within the industry.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?